IBA SA : IBA signs contract for additional treatment capacity at Latin America's first proton therapy center in Argentina
IBA signs contract for additional treatment capacity at Latin America's
first proton therapy center in Argentina
Contract for additional gantry treatment room for Proteus®PLUS solution,
already under construction
Louvain-la-Neuve, Belgium, January 5, 2018 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has signed a new contract with INVAP for an additional gantry treatment room at the CNEA - UBA New Technologies Cancer Treatment Center to be installed in Buenos Aires, Argentina, in a collaboration between CNEA, UBA (University of Buenos Aires), and other institutions. This new equipment order has been booked in 2017 and is worth between EUR 10 and 15 million to IBA, including a multi-year service agreement. IBA expects to receive a down payment for this new contract in the coming weeks.
In September 2015, IBA signed its first collaboration contract with INVAP and CNEA (Comisión Nacional de Energia Atómica) to install the first proton therapy system in Latin America. The Proteus®PLUS* solution will now include two gantry treatment rooms with next generation Pencil Beam Scanning capability and integrated Cone Beam CT as well as a dedicated research room. The center will also benefit from the most advanced room matching available, enabling maximum flexibility of room scheduling and allowing for a minimum 30% reduction in commissioning time therefore giving maximum flexibility for patient treatment.
Olivier Legrain, Chief Executive Officer of IBA commented: "The extension of our collaboration with INVAP endorses IBA's position as the trusted partner for the development and delivery of proton therapy treatment facilities around the world. We are delighted to expand on our original agreement to install the first proton therapy system in Latin America as it will give improved access to this life changing treatment to more patients globally."
Alberto Lamagna, Vice President of CNEA, commented: "By bringing an innovative new cancer center closer to the people that need it, doctors have a greater variety of methods to treat cancer. Proton therapy is used today to treat a wide range of cancers and it can be used where treatment options were previously limited. Proton therapy has the potential to improve treatment results and decrease the risk of secondary effects or long-term complications, leading to improved patients' quality of life.
"This collaboration between CNEA, INVAP and IBA, the global leader in proton therapy, is significant and an important milestone for our future long-term partnerships with these organizations to benefit more cancer patients in Argentina and Latin America."
Notes to Editors
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
*Proteus®PLUS is a brand name of Proteus®235
INVAP is an Argentinian company devoted to the design and construction of complex technological systems, with more than 40 years of history in the domestic market and more than twenty in the international scene. Its mission is to develop state-of-the-art technology in different industrial, scientific and applied research fields, thus creating "technological packages" with high added value, to meet domestic requirements or to be exported to international markets. www.invap.com.ar/en/
For further information, please contact:
Chief Financial Officer
+32 10 475 890
Vice-President Corporate Communication
+32 10 475 890
For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700